[{"Assets_0_Q2_USD":74703000.0,"CommonStockSharesOutstanding_0_Q2_shares":2344362.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-7757000.0,"NetIncomeLoss_1_Q2_USD":-5568000.0,"NetIncomeLoss_2_Q2_USD":-11032000.0,"StockholdersEquity_0_Q2_USD":-25177000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":657000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":1099000.0,"Ticker":"CRNX","CIK":"1658247","name":"CRINETICS PHARMACEUTICALS, INC.","OfficialName":"Crinetics Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1104302360.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20180830"}]